Cardlytics Valuation
| CDLX Stock | USD 2.38 0.09 3.64% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Cardlytics shows a prevailing Real Value of $2.83 per share. The current price of the firm is $2.38. Our model approximates the value of Cardlytics from analyzing the firm fundamentals such as Profit Margin of (0.68) %, return on equity of -1.85, and Current Valuation of 283.06 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Cardlytics' valuation include:
Price Book 1.8384 | Enterprise Value | Enterprise Value Ebitda (7.69) | Price Sales 0.4623 | Enterprise Value Revenue 0.9645 |
Undervalued
Today
Please note that Cardlytics' price fluctuation is very risky at this time. Calculation of the real value of Cardlytics is based on 3 months time horizon. Increasing Cardlytics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Cardlytics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cardlytics Stock. However, Cardlytics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.38 | Real 2.83 | Target 4.4 | Hype 2.24 |
The intrinsic value of Cardlytics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Cardlytics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Cardlytics helps investors to forecast how Cardlytics stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cardlytics more accurately as focusing exclusively on Cardlytics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Cardlytics' intrinsic value based on its ongoing forecasts of Cardlytics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Cardlytics' closest peers.
Cardlytics Cash |
|
Cardlytics Valuation Trend
Analysing the historical paterns of Cardlytics' enterprise value and its market capitalization is a good way to estimate and gauge the value of Cardlytics over time and is usually enough for investors to make rational market timing decisions.
Cardlytics Revenue by Product
Cardlytics Total Value Analysis
Cardlytics is currently expected to have valuation of 283.06 M with market capitalization of 128.65 M, debt of 221.65 M, and cash on hands of 157.04 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Cardlytics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
283.06 M | 128.65 M | 221.65 M | 157.04 M |
Cardlytics Investor Information
About 58.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.84. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cardlytics recorded a loss per share of 6.4. The entity had not issued any dividends in recent years. Based on the key indicators related to Cardlytics' liquidity, profitability, solvency, and operating efficiency, Cardlytics may be sliding down financialy. It has an above-average likelihood of going through some form of financial trouble next quarter.Cardlytics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cardlytics has an asset utilization ratio of 70.87 percent. This suggests that the Company is making $0.71 for each dollar of assets. An increasing asset utilization means that Cardlytics is more efficient with each dollar of assets it utilizes for everyday operations.Cardlytics Ownership Allocation
Cardlytics holds a total of 52.09 Million outstanding shares. Over half of Cardlytics' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Cardlytics Profitability Analysis
The company reported the previous year's revenue of 278.3 M. Net Loss for the year was (189.3 M) with profit before overhead, payroll, taxes, and interest of 120.89 M.About Cardlytics Valuation
Our relative valuation model uses a comparative analysis of Cardlytics. We calculate exposure to Cardlytics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cardlytics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 278.3 M | 292.2 M | |
| Pretax Profit Margin | (0.68) | (0.71) | |
| Operating Profit Margin | 0.43 | 0.45 | |
| Net Loss | (0.68) | (0.71) | |
| Gross Profit Margin | 0.38 | 0.30 |
Cardlytics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 48.4 M | |
| Quarterly Earnings Growth Y O Y | -0.567 |
Cardlytics Current Valuation Indicators
Valuation refers to the process of determining the present value of Cardlytics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Cardlytics we look at many different elements of the entity such as Cardlytics's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Cardlytics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Cardlytics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Cardlytics' worth.Additional Tools for Cardlytics Stock Analysis
When running Cardlytics' price analysis, check to measure Cardlytics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardlytics is operating at the current time. Most of Cardlytics' value examination focuses on studying past and present price action to predict the probability of Cardlytics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardlytics' price. Additionally, you may evaluate how the addition of Cardlytics to your portfolios can decrease your overall portfolio volatility.